Bausch Health Companies (NYSE:BHC - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $2.51 billion for the quarter. Parties interested in listening to the company's conference call can do so using this link.
Bausch Health Companies Stock Performance
Shares of NYSE:BHC traded down $0.23 during midday trading on Friday, reaching $6.15. 2,935,985 shares of the company's stock traded hands, compared to its average volume of 3,757,992. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -12.82, a P/E/G ratio of 0.34 and a beta of 0.68. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The stock has a 50 day moving average of $7.48 and a 200 day moving average of $7.46.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on BHC shares. Royal Bank of Canada lowered their target price on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating on the stock in a report on Thursday, January 30th. StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Finally, Jefferies Financial Group restated a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Bausch Health Companies presently has an average rating of "Hold" and a consensus price target of $7.42.
View Our Latest Stock Report on BHC
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Stories
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
